急性缺血性卒中使用组织型纤溶酶原激活剂的法医学问题。
Medico-legal aspects of using tissue plasminogen activator in acute ischemic stroke.
作者信息
Bruce Nhu T, Neil William P, Zivin Justin A
机构信息
San Diego VA Healthcare System, Neurology Service (127), 3350 La Jolla Village Drive, San Diego, CA, 92161, USA.
出版信息
Curr Treat Options Cardiovasc Med. 2011 Jun;13(3):233-9. doi: 10.1007/s11936-011-0122-0.
Abstract
Intravenous alteplase or tissue plasminogen activator (tPA) has been the standard of care with proven efficacy for acute ischemic stroke for over a decade. Despite this, only a small fraction of potentially eligible stroke patients receive this medication. There seems to be a fear among practitioners of legal repercussions as a result of an increased risk of intracerebral hemorrhage due to tPA. This review of legal cases involving tPA will show that instead, physicians are often found liable as a result of not treating with tPA.
摘要
静脉注射阿替普酶或组织纤溶酶原激活剂（tPA）十多年来一直是急性缺血性卒中经证实有效的标准治疗方法。尽管如此，只有一小部分可能符合条件的卒中患者接受这种药物治疗。由于tPA导致脑出血风险增加，从业者似乎担心会有法律后果。对涉及tPA的法律案件的审查将表明，相反，医生往往因未使用tPA进行治疗而被认定有责任。
相似文献
1
Medico-legal aspects of using tissue plasminogen activator in acute ischemic stroke.急性缺血性卒中使用组织型纤溶酶原激活剂的法医学问题。
Curr Treat Options Cardiovasc Med. 2011 Jun;13(3):233-9. doi: 10.1007/s11936-011-0122-0.
2
Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape.组织型纤溶酶原激活剂与急性缺血性中风患者：诉讼情况
J Am Coll Emerg Physicians Open. 2022 Jan 22;3(1):e12646. doi: 10.1002/emp2.12646. eCollection 2022 Feb.
3
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.静脉注射组织型纤溶酶原激活剂治疗急性中风：阿替普酶逆转中风标准治疗（STARS）研究
JAMA. 2000 Mar 1;283(9):1145-50. doi: 10.1001/jama.283.9.1145.
5
Observational study of telephone consults by stroke experts supporting community tissue plasminogen activator delivery.卒中专家通过电话咨询支持社区组织型纤溶酶原激活物输送的观察性研究。
Acad Emerg Med. 2012 Sep;19(9):E1027-34. doi: 10.1111/j.1553-2712.2012.01438.x.
6
Intravenous tissue plasminogen activator for acute ischemic stroke in patients with renal dysfunction.静脉注射组织型纤溶酶原激活剂用于肾功能不全患者的急性缺血性卒中治疗
QJM. 2022 Jan 9;114(12):848-856. doi: 10.1093/qjmed/hcaa237.
7
Medicolegal considerations with intravenous tissue plasminogen activator in stroke: a systematic review.静脉注射组织型纤溶酶原激活剂治疗中风的法医学考量：一项系统综述
Stroke Res Treat. 2013;2013:562564. doi: 10.1155/2013/562564. Epub 2013 Sep 4.
8
Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.缺血性卒中的静脉注射组织型纤溶酶原激活剂治疗：休斯顿1996年至2000年的经验
Arch Neurol. 2001 Dec;58(12):2009-13. doi: 10.1001/archneur.58.12.2009.
9
Role of tissue plasminogen activator in acute ischemic stroke.组织型纤溶酶原激活物在急性缺血性脑卒中中的作用。
Ann Pharmacother. 2011 Mar;45(3):364-71. doi: 10.1345/aph.1P525. Epub 2011 Mar 8.
10
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.接受华法林治疗的急性缺血性脑卒中患者接受静脉注射组织型纤溶酶原激活物治疗后的颅内出血风险。
JAMA. 2012 Jun 27;307(24):2600-8. doi: 10.1001/jama.2012.6756.
引用本文的文献
1
Legal medicine implications in fibrinolytic therapy of acute ischemic stroke.法医学在急性缺血性脑卒中溶栓治疗中的应用。
BMC Med Ethics. 2019 Oct 14;20(1):70. doi: 10.1186/s12910-019-0412-8.
2
Real-World Effectiveness of Intravenous Stroke Thrombolysis is more than the Expectation of Practicing Neurologists.静脉溶栓治疗卒中的真实世界有效性超出了执业神经科医生的预期。
J Neurosci Rural Pract. 2018 Jul-Sep;9(3):331-335. doi: 10.4103/jnrp.jnrp_37_18.
3
Emergency Neurological Life Support: Acute Ischemic Stroke.急诊神经生命支持：急性缺血性脑卒中。
Neurocrit Care. 2017 Sep;27(Suppl 1):102-115. doi: 10.1007/s12028-017-0449-9.
4
Observational study of telephone consults by stroke experts supporting community tissue plasminogen activator delivery.卒中专家通过电话咨询支持社区组织型纤溶酶原激活物输送的观察性研究。
Acad Emerg Med. 2012 Sep;19(9):E1027-34. doi: 10.1111/j.1553-2712.2012.01438.x.
本文引用的文献
1
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.静脉注射重组组织型纤溶酶原激活剂治疗时间与卒中转归：ECASS、ATLANTIS、NINDS 和 EPITHET 试验的更新汇总分析。
Lancet. 2010 May 15;375(9727):1695-703. doi: 10.1016/S0140-6736(10)60491-6.
2
Hot topics in risk management in neurologic practice.神经科实践中的风险管理热点问题。
Neurol Clin. 2010 May;28(2):429-39. doi: 10.1016/j.ncl.2009.11.005.
3
Review of tissue plasminogen activator, ischemic stroke, and potential legal issues.组织型纤溶酶原激活剂、缺血性中风及潜在法律问题综述
Arch Neurol. 2008 Nov;65(11):1429-33. doi: 10.1001/archneur.65.11.1429.
4
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.急性缺血性卒中发病3至4.5小时后使用阿替普酶进行溶栓治疗。
N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.
5
Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke.涉及组织型纤溶酶原激活剂和缺血性中风的诉讼的实证特征。
Ann Emerg Med. 2008 Aug;52(2):160-4. doi: 10.1016/j.annemergmed.2007.12.017. Epub 2008 Mar 7.
6
Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm.卒中溶栓治疗后的出血：临床相关伤害所需的病例数
Stroke. 2007 Aug;38(8):2279-83. doi: 10.1161/STROKEAHA.107.487009. Epub 2007 Jul 19.
7
Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.中风中的溶栓治疗（组织型纤溶酶原激活剂）：一个法医学难题。
Stroke. 2006 Jul;37(7):1917-22. doi: 10.1161/01.STR.0000226651.04862.da. Epub 2006 May 25.
8
Reasons why few patients with acute stroke receive tissue plasminogen activator.急性中风患者中很少有人接受组织型纤溶酶原激活剂治疗的原因。
Arch Neurol. 2006 May;63(5):661-4. doi: 10.1001/archneur.63.5.661.
9
Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke.纳入临床结局全范围效应的需治疗人数估计：新的推导方法及其在急性卒中溶栓治疗中的应用
Arch Neurol. 2004 Jul;61(7):1066-70. doi: 10.1001/archneur.61.7.1066.
10
Thrombolysis with fibrinolysin in cerebral arterial occlusion.纤溶酶在脑动脉闭塞中的溶栓作用。
J Am Med Assoc. 1958 Aug 2;167(14):1705-9. doi: 10.1001/jama.1958.02990310011002.
Zotero 插件